Abeona Therapeutics (ABEO) Projected to Post Quarterly Earnings on Thursday

Abeona Therapeutics (NASDAQ:ABEO) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $5.5330 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 7:30 AM ET.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, beating the consensus estimate of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $21.71 million. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO opened at $4.36 on Thursday. The company has a market cap of $223.58 million, a price-to-earnings ratio of 6.23 and a beta of 1.42. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.73 and a quick ratio of 6.65. The firm has a 50 day simple moving average of $5.69 and a 200 day simple moving average of $6.02. Abeona Therapeutics has a one year low of $3.93 and a one year high of $7.54.

Insider Buying and Selling at Abeona Therapeutics

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $5.24, for a total value of $131,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,190,067 shares in the company, valued at approximately $6,235,951.08. This represents a 2.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Brendan M. O’malley sold 9,366 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $5.39, for a total transaction of $50,482.74. Following the completion of the transaction, the senior vice president owned 350,763 shares of the company’s stock, valued at approximately $1,890,612.57. This trade represents a 2.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 63,612 shares of company stock worth $339,171. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Corient Private Wealth LLC acquired a new stake in shares of Abeona Therapeutics during the second quarter worth $127,000. Man Group plc acquired a new stake in shares of Abeona Therapeutics during the second quarter worth $67,000. BNP Paribas Financial Markets acquired a new stake in shares of Abeona Therapeutics during the second quarter worth $749,000. Bank of America Corp DE increased its position in shares of Abeona Therapeutics by 154.9% during the second quarter. Bank of America Corp DE now owns 329,884 shares of the biopharmaceutical company’s stock worth $1,874,000 after buying an additional 200,469 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Abeona Therapeutics by 14.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock worth $17,455,000 after buying an additional 381,357 shares during the period. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ABEO shares. Oppenheimer increased their price objective on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, August 15th. Weiss Ratings downgraded shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research note on Monday, October 13th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.